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Deaminase activity mediated by the human
APOBEC3 family of proteins contributes to genomic
instability and cancer. APOBEC3A is by far the
most active in this family and can cause rapid cell
death when overexpressed, but in general how the
activity of APOBEC3s is regulated on a molecular
level is unclear. In this study, the biochemical and
structural basis of APOBEC3A substrate binding
and specificity is elucidated. We find that specific
binding of single-stranded DNA is regulated by the
cooperative dimerization of APOBEC3A. The crystal
structure elucidates this homodimer as a symmetric
domain swap of the N-terminal residues. This dimer
interface provides insights into how cooperative pro-
tein-protein interactions may affect function in the
APOBEC3 enzymes and provides a potential scaffold
for strategies aimed at reducing their mutation load.
INTRODUCTION
Several exogenous and endogenous factors act as mutagens,
contributing to carcinogenesis. The APOBEC3 proteins have
been described as a major endogenous source for mutations
in various types of cancer. Acting on chromosomal DNA, the
APOBEC3 family of cytidine deaminases can introduce G-to-A
hypermutations, as observed in clusters of APOBEC3-mediated
mutational signatures found in breast cancer genomes (Nik-Zai-
nal et al., 2012). APOBEC3B (A3B) was recently identified as a
direct enzymatic source for this type of clustered mutation
(Burns et al., 2013a). In addition to breast cancer, several other
cancers such as bladder cancer, head and neck cancer, cervical
cancer, and lung cancer exhibit a similar genomic mutation
pattern (Burns et al., 2013b; Roberts et al., 2013). Urothelial
bladder cancer exhibits the most pronounced contribution of
APOBEC3-mediated hypermutations to the overall mutation
load (Cancer Genome Atlas Research Network, 2014). In lung
cancer, APOBEC3-induced genomic instability appears to in-
crease over time as the tumor progresses (de Bruin et al.,Structure 232014). APOBEC3A (A3A) shares the same genomic locus as
A3B but is much more catalytically active and potentially linked
to breast cancer (Caval et al., 2014; Nik-Zainal et al., 2014).
APOBEC3 proteins belong to a superfamily of deaminases
and catalyze a cytidine to uridine zinc-dependent deamination
reaction (Betts et al., 1994; Wilson et al., 1991). Common
ancestry links the seven proteins of the contiguous human
APOBEC3 locus (Wedekind et al., 2003) and allows classification
based on phylogeny (LaRue et al., 2009). A3A, A3C, and A3H
comprise a single, catalytically active deaminase domain,
whereas A3B, A3D, A3F, and A3G are two-domain proteins
with an N-terminal pseudocatalytic deaminase domain (NTD)
and a C-terminal catalytic domain (CTD). The spatial extent of
the substrate accommodating the active site region appears to
be a determinant of whether a deaminase domain exhibits cata-
lytic activity or not (Shandilya et al., 2014). The APOBEC3 pro-
teins act on ssDNA to introduce strand-coordinated G-to-A point
mutations. These mutations not only compromise the informa-
tional integrity of DNA but may also lead to double strand breaks
(Burns et al., 2013a; Landry et al., 2011) contributing to genomic
damage observed in the cancer genomes (Roberts et al., 2012;
Sakofsky et al., 2014).
Four members of the APOBEC3 family (A3D, A3F, A3G, and
A3H) apply strong selective pressure on HIV-1 in the absence
of Vif (Bishop et al., 2004; Dang et al., 2006; Harari et al., 2009;
Harris et al., 2003; Hultquist et al., 2011; Lecossier et al., 2003;
Liddament et al., 2004; Mangeat et al., 2003; OhAinle et al.,
2008; Sheehy et al., 2002; Wiegand et al., 2004; Zhang et al.,
2003; Zheng et al., 2004). These proteins are incorporated into
budding virions and, upon subsequent infection of a target cell,
introduce point mutations in the newly reverse-transcribed viral
genomic ssDNA, leading to direct degradation of the highly
mutated product (Weil et al., 2013) or detrimental G-to-A muta-
tions (Harris et al., 2003; Loeb et al., 1999).
A3G and A3F form high molecular mass complexes with poly-
nucleotides that are relevant for biological function (Wang et al.,
2007; Wedekind et al., 2006). The four antiretroviral APOBEC3
proteins were recently demonstrated to form multimeric com-
plexes in living cells (Li et al., 2014). Over the last few years,
atomic force microscopy (AFM) studies have provided insights
into the mechanistic details influencing this complex formation
(Shlyakhtenko et al., 2011, 2013, 2014). The crystal structures
of A3C (Kitamura et al., 2011), A3F-CTD (Bohn et al., 2013),, 903–911, May 5, 2015 ª2015 Elsevier Ltd All rights reserved 903
Figure 1. APOBEC3A Binding Specifically to Trinucleotide Deamination Motifs
(A) Fluorescence anisotropy measurements show how introduction of a single TTCmotif in a polyA background leads to high affinity binding. Other motifs have a
similar effect, but TTC appears to be the preferred substrate.
(B) APOBEC3A binding to an ideal substrate consisting of a polyT oligomer containing a single cytidine residue. Varying the number of cytidines does not have any
pronounced effect on APOBEC3A affinity.
(C) Difference in affinity to the target deamination site versus a polyT oligomer. Binding is cooperative with higher affinity to the oligomer containing the TTCmotif
(polyT_1C). APOBEC3A has the same affinity to the deaminated base (polyT_1U) as to the polyT background. Binding is specific to the substrate and not to the
product.
The error bars represent the SD calculated for each measurement point from three independent repeats. See also Figures S2 and S3.and A3G-CTD (Holden et al., 2008; Li et al., 2012; Shandilya
et al., 2010), and the nuclear magnetic resonance (NMR) struc-
tures of A3G-CTD (Chen et al., 2008; Harjes et al., 2009) and
A3A (Byeon et al., 2013) have provided further insights into the
structural factors influencing this activity. However, significant
details are still missing due to the lack of APOBEC3-ssDNA com-
plex structures that could illuminate the molecular basis of com-
plex formation.
The functional oligomerization state of A3 enzymes and
whether or not cooperativity contributes to DNA binding affinity
are not clear. The two-domain A3G binds ssDNA both as a
monomer and dimer, but the dimerization is not induced by
ssDNA binding (Shlyakhtenko et al., 2013), which is consistent
with the observation that A3G binds its substrate noncoopera-
tively (Chelico et al., 2006, 2008) with high affinity (KD  50–
75 nM) (Chelico et al., 2006; Iwatani et al., 2006; Yu et al., 2004).
The single-domain A3A has been reported to be monomeric
in vitro, in solution, as detected by AFM (Shlyakhtenko et al.,
2014), as well as in living cells monitored by fluorescence fluctu-
ation spectroscopy (FFS) (Li et al., 2014). The binding affinity of
catalytically active A3A to ssDNA substrate, compared with
A3G, is reported to be lower by 100-fold (Byeon et al., 2013;
Mitra et al., 2014) or 50-fold (Love et al., 2012), depending on
the chosen experimental conditions. These reports are further
complicated by the observation that catalytically active A3A is
the most potent enzyme of the A3 family, with deamination rates
up to 10-fold above those of APOBEC3G (Carpenter et al., 2012).904 Structure 23, 903–911, May 5, 2015 ª2015 Elsevier Ltd All rightsCatalytically inactive A3A, on the other hand, dimerizes readily
on the target ssDNA substrate (Shlyakhtenko et al., 2014). How-
ever, catalytically inactive A3A can bind substrates with similar
affinity as A3G (Logue et al., 2014). The fundamental reasons
for these apparent discrepancies are not well understood.
In this study we explore the structural and biochemical basis
underlying A3A ssDNA binding activity and the direct functional
impact of cooperative dimerization on binding affinity. We devel-
oped a novel fluorescence anisotropy-based high-throughput
binding assay, solved a high-resolution crystal structure, and
generated a range of A3A mutants to demonstrate that catalyti-
cally inactive A3A binds ssDNA with high affinity and specificity
while exhibiting a high degree of cooperativity. Cooperative
dimerization of APOBEC3A provides fundamental insights into
the function of the entire APOBEC3 family of proteins and their
respective roles in anti-retroviral and anti-cancer therapies.
RESULTS
APOBEC3A Preferentially Binds the TTC Trinucleotide
Sequence
APOBEC3 enzymes recognize target deamination site cytidines
within the context of specific trinucleotide motifs. A binding
assay was developed using short, fluorescently labeled 15-mer
oligonucleotides with single target sites for deamination to quan-
titatively assess motif specificity. A catalytically inactive mutant
of A3A (E72A/C171A) (Figure 1A; Table 1) was used and thereserved
Table 1. ssDNA Binding Affinity and Cooperativity of APOBEC3A
and Interface Mutants
KD (nM)
KD Relative
to polyT_1C nH
A3A vs TTC 77 ± 3 1.4 2.1 ± 0.1
A3A vs TCC 114 ± 4 2.0 2.5 ± 0.2
A3A vs CCC 100 ± 4 1.8 2.1 ± 0.2
A3A vs polyT_1C 56 ± 2 1.0 1.8 ± 0.1
A3A vs polyT_2C 44 ± 2 0.8 1.6 ± 0.1
A3A vs polyT_3C 59 ± 2 1.1 2.2 ± 0.1
A3A vs polyT_4C 61 ± 3 1.1 1.7 ± 0.1
A3A vs polyT 502 ± 27 9.0 0.96 ± 0.04
A3A vs polyT_1U 434 ± 35 7.8 0.80 ± 0.04
A3A H11A vs polyT_1C 855 ± 311 15.3 0.7 ± 0.1
A3A H16A vs polyT_1C 584 ± 92 10.4 1.2 ± 0.2
A3A K30E vs polyT_1C 284 ± 20 5.1 1.2 ± 0.1
A3A H56A vs polyT_1C 86 ± 13 1.5 0.9 ± 0.1
A3A E72Q vs polyT_1C 26 ± 2 0.5 1.8 ± 0.1
A3A E72Q vs polyT_1U 296 ± 125 5.3 1.0 ± 0.2
A3A E72Q vs polyT 205 ± 20 3.7 1.4 ± 0.2
The Hill coefficient (nH) is expected to be 1 for noncooperative binding
and 2 for cooperative binding by a dimer. A3A refers to the inactive variant
E72A. Fold-changes in KD (second column) are relative to polyT_1C sub-
strate (bold type). See also Table S1 for oligomer sequences.dissociation constant determined for several trinucleotide deam-
ination motifs. This variant of A3A binds the target trinucleotide
motif (50-TTC-30) with high affinity (KD = 77 ± 3 nM) and strong
specificity compared with an adenine polynucleotide. This affin-
ity is comparable with that reported for A3G (Chelico et al., 2006).
Other cytidine-containing trinucleotide motifs known to be sub-
strates for A3A are bound with similar affinities, KD = 114 ±
4 nM for 50-TCC-30 and KD = 100 ± 4 nM for 50-CCC-30. These
data are consistent with previously reported values for trinucleo-
tide motifs (Love et al., 2012) but in our observations 50-TTC-30 is
slightly more preferred with a 20–30 nM difference in KD.
Using substrates based on the high-affinity trinucleotide
(50-TTC-30) a poly-thymidine oligomer containing two cytidine
bases was identified as the tightest binding partner for A3A (Fig-
ure 1B; Table 1) with KD = 44 ± 2 nM. Varying the number of
consecutive cytidines, ranging from one to four, did not signifi-
cantly alter substrate affinity. An oligonucleotide consisting
solely of thymidine, lacking cytidine, binds to the enzyme (Fig-
ure 1C) but the affinity is an order of magnitude weaker than in
the presence of a single cytidine (KD = 502 ± 27 nM).
A second parameter undergoing change upon introducing
a target site is the Hill coefficient of the binding curve.
When the substrate contains a cytidine, the Hill coefficient
is 2 (Figures 1A and 1B; Table 1), whereas the Hill coefficient
is 1 in the absence of a cytidine. This difference in the Hill
coefficient may imply that APOBEC3A is in a monomeric low-
affinity state in the absence of a target cytidine but assumes a
dimeric high-affinity state when encountering a deamination
substrate. Such a binding mechanism would predict that the
affinity to the product of the deamination reaction would likely
also be weaker. To test this hypothesis, we replaced the cytidineStructure 23base with a uracil, in which case both the affinity and the Hill
coefficient are similar to those for the all-thymidine oligomer
(1U KD = 434 ± 35 nM, h = 0.80 ± 0.04; TTT KD = 502 ± 27 nM,
h = 0.96 ± 0.04) (Figure 1C; Table 1).
Crystal Structure of APOBEC3A
The crystal structure of A3A-E72A-C171A was determined to
2.85 A˚ resolution with two molecules per asymmetric unit (Fig-
ure 2A) forming a homodimer. The A3A dimer crystallized in
space group P6522 and refined with good statistics (Table 2).
As observed in the NMR solution structure (Byeon et al., 2013),
A3A has a canonical DNA cytosine deaminase fold, composed of
five b-strands, six a-helices, and the catalytic zinc-binding site.
The zinc atom is coordinated by direct interactions with H70,
C101, C106, and, as the catalytic glutamic acid (E72A) is inac-
tive, to what appears to be a second zinc ion which is 3.3 A˚ apart
from and appears to stabilize the geometry around the catalytic
zinc (Figure 2B). This type of site with two zinc ions in close prox-
imity resembles cocatalytic zinc sites, which can be found in
class III hydrolases (Auld, 2001). Comparing with the NMR
ensemble of catalytically active A3A (Byeon et al., 2013) shows
that the loop connecting the zinc-coordinating cysteine residues
has moved, which is necessary to conserve the active-site ge-
ometry in the presence of the E72A mutation and allows recruit-
ment of T31 to coordinate the second ion. This loop contains
104-WG-105, an insertion unique to A3A and the closely related
C-terminal domain of A3B. All zinc-coordinating residues are
located in helices a2 and a3, which also provide a structural
backbone for the catalytic pocket.
The crystal structure reveals that A3A forms a dimer that de-
fines the asymmetric unit. This dimer is formed via a symmetric
domain swap between two A3A molecules. The root-mean-
square deviation (RMSD) between the two molecules is 0.64 A˚
with the largest deviations in residues 25–27, 50, and 86–87
with Ca-Ca distances of 1.3 A˚ (Figure S1). Seventeen residues
that form the N-terminal loop regions of both molecules form
an intimate handshake (Figure 2A) burying >1,000 A˚2 acting as
the dimerization interface. The dimerization interface is away
from the active sites and coordinates three metal ions by
residues H11 and H56 from both chains and a network of water
molecules. In addition, the side chains of residues K30 are coor-
dinated via a water molecule at the interface bridging the two
molecules (Figure 3A).
On the surface of the dimer (Figure 2C), a symmetric groove
36 A˚ in length connects the active site regions of the two mole-
cules via the dimerization interface. This groove has been iden-
tified as a potential ligand binding site with a calculated (Halgren,
2009) pocket volume of 800 A˚3 (Figure 2D). Based on surface
electrostatic potential, the groove is mostly positively charged
(Figure 2E). Residues H16, R28, K30, H56, and K60 are promi-
nently contributing to both the accessible pocket volume and
charge.
Assessing the Functional Significance of the
Crystallographic Dimer
The crystal structure allowed us to identify and test the potential
determinants for substrate recognition and binding. Based on
the crystallographic dimer, we engineered a series of mutant
constructs to probe whether the observed dimer might play a, 903–911, May 5, 2015 ª2015 Elsevier Ltd All rights reserved 905
Figure 2. Crystal Structure of APOBEC3A
(A) Crystallographic dimer of APOBEC3A. The two monomers are in orange and cyan, with the metal ions at the active sites depicted as steel gray spheres and
chloride ions at the dimerization interface shown as green spheres.
(B) Close-up view of the active site. Recruitment of a secondmetal via a threonine residue (T31) protects active site geometry in the presence of a mutation of the
catalytic glutamate residue.
(C) Surface representation of the dimeric structure in (A) reveals a groove connecting both active sites via the dimer interface.
(D) SiteMap prediction (Halgren, 2009) of putative binding sites (blue) on a wireframe representation of the surface in (C) matches the groove connecting both
active sites.
(E) Electrostatic potential map, same orientation as (A) and (C). Positive (blue) and negative (red) charges are indicated on the surface. The groove connecting the
two active sites is mainly positively charged. See also Figure S1 for a superposition of both monomers.role in substrate binding. If the crystallographic dimer indeed
corresponds to a biochemically relevant structure, then the de-
signed mutations should affect and provide insights into sub-
strate recognition.
Since the crystallographic interface brings the N-terminal
17 residues in close proximity, we tested an N-terminally
truncated version of A3A to investigate the potential role of the906 Structure 23, 903–911, May 5, 2015 ª2015 Elsevier Ltd All rightscrystallographic dimer as the structure responsible for the
observed cooperativity. Under the same experimental condi-
tions as used above, the truncated protein lost the high affinity
to the ideal substrate (Figure S2), and protein expression yields
and the construct solubility were severely compromised.
In order to confirm that the active site rearrangement
caused by the E72A mutation did not cause the observedreserved
Table 2. Crystallographic Statistics for APOBEC3A Structure
Resolution (A˚) 2.85
Temperature Cryogenic (180C)
Space group P6522
Cell dimensions
a (A˚) 94.75
b (A˚) 94.75
c (A˚) 213.96
a () 90.00
b () 90.00
g () 120.00
Molecules (AU) 2
Completeness (%) 99.7
Total reflections 153,753
Unique reflections 14,142
I/sI (mean) 7.0
I/sI (outer shell) 0.6
Average redundancy 11.0
rmerge (linear) 0.239
rmeas 0.251
rpim 0.091
CC1/2 (outer shell) 0.665
CC* (outer shell) 0.894
RMSD in
Bonds (A˚) 0.002
Angles () 0.59
Rfactor 0.21
Rfree 0.25differential substrate recognition, we repeated the binding
experiment presented in Figure 1C with an E72Q variant.
A3A E72Q exhibits the same kind of marked increase in affin-
ity and cooperativity upon encountering the target cytidine
(Figure S3; Table 1).
The crystal structure was further used to narrow down the de-
terminants for dimerization and identify sites amenable to single
amino acid substitutions based on the charge distribution and
interatomic distances described above. A series of mutant pro-
teins were then engineered to measure the contribution of these
individual amino acids to cooperativity and affinity (Figure 3).
From the structure, two pairs of residues were identified that
might contribute to dimer formation. H11 and H56 are the first
set, which forms the base of the dimerization interface (Fig-
ure 3A), andmutations at these residues not only disrupt the pro-
tein-protein interface but also severely affect cooperativity of
binding (H11A, KD = 855 ± 311 nM, h = 0.7 ± 0.1; H56A, KD =
86 ± 13 nM, h = 0.9 ± 0.1). A second set of ionic residues, H16
and K30, closer to the surface (Figure 3A) of the groove also
markedly reduce cooperatively and greatly compromise affinity
when mutated (H16A, KD = 584 ± 92 nM, h = 1.2 ± 0.2; K30E,
KD = 284 ± 20 nM, h = 1.2 ± 0.1) and greatly compromise affinity.
H56A was the only mutation drastically reducing cooperativity
while maintaining substrate affinity. The results show that both
sets of interactions predicted by the dimerization interfaceStructure 23observed in the crystal structure are critical to cooperative
DNA recognition in solution.
DISCUSSION
In this study, we characterized the cooperativity in specific bind-
ing of A3A to ssDNA substrate, determined the crystal structure
of the A3A dimer, and engineeredmutations that interrogated the
functional implications of this dimer interface. We found that A3A
recognizes substrate cooperatively and with high affinity and
specificity. Key to this recognition is the A3A dimer that forms
an extensive positively charged groove connecting the active
sites of both monomers. A3A exists as a monomer and as a
dimer both in solution and bound to substrate (Logue et al.,
2014; Shlyakhtenko et al., 2014) yet a functional implication for
transition between those states was missing. The identification
of this substrate-binding groove and mutational analysis provide
key insights into the structural basis of A3A substrate specificity,
and helps to explain the previously reported apparent discrep-
ancies on A3A function.
The contiguous and positively charged groove on the A3A sur-
face is consistent with DNA recognition and binding. In fact,
many residues around the active site region appear to be
involved in substrate binding. Our structure unifies many of the
residues previously associated with ssDNA binding to A3A (Bul-
liard et al., 2011; Byeon et al., 2013; Mitra et al., 2014) by map-
ping them to a contiguous band on the molecular surface
crossing the dimer interface (Figure 4; Figure S4). This bridges
the data from the two previous studies where only relatively
few residues identified were overlapping (Figure 4, yellow);
most likely the experimental conditions account for the differ-
ences (Figure 4, green, Mitra et al., 2014; and red, Bulliard
et al., 2011). Our crystal structure demonstrates the consistency
of both studies in that all residues identified by either study lie
within the groove. In fact, two residues outside the active site
identified in both studies, K30 and K60, that bridge the dimer
interface and contribute to the groove’s charge, respectively,
affect substrate affinity and deamination (Bulliard et al., 2011;Mi-
tra et al., 2014). The H56Amutant, which has a significant impact
on dimerization and a much smaller effect on substrate affinity,
seems to allow a separation of function and shows that high
affinity can be achieved in the monomeric state as well.
Although A3A can and does exist in monomeric form in
solution and in the cell (Li et al., 2014; Logue et al., 2014;
Shlyakhtenko et al., 2014), our analysis strongly implies that
the high-affinity DNA-binding functional form is a homodimer
formed by swapping the N-terminal loop. A naturally occurring
isoform of A3A, which lacks the initial 12 residues (Stenglein
et al., 2010; Thielen et al., 2010), was described to be 5-fold
less active compared with the full-length enzyme (Carpenter
et al., 2012) in an in vitro deamination assay. This only modest
reduction in activity could arise from key residues of the interface
lying outside the N-terminus. Dimerization via the N-terminus
could be communicated via K30 and H56, which are involved
in interface formation, to neighboring residues T31 and N57
forming the pocket containing the catalytic site. Residues H56
and K30, which form the top of the groove of the dimerization
interface, are also positioned to favorably interact with the nega-
tively charged phosphates of the substrate and thus can not only, 903–911, May 5, 2015 ª2015 Elsevier Ltd All rights reserved 907
Figure 3. Residues Contributing to Interface Formation Are Determinants for Cooperativity and Affinity
(A) The dimer interface in the APOBEC3A crystal structure. Residues forming the dimerization interface are shown as sticks and zinc (gray), chloride (green), and
water (red) as spheres. Side-chain oxygen and nitrogen atoms are colored red and green, respectively.
(B) Bar graphs show how point mutations at the highlighted sites affect KD and the Hill coefficient. WT represents data collected for A3A-E72A-C171A. KD (rel.)
represents the fold change in KD relative to A3A-E72A-C171A binding polyT_1C. The error bars represent the SD from three independent repeats.communicate dimerization, but, more specifically, dimerization
on the substrate to the active site region.
The necessity for A3A to form a cooperative dimer for high-
affinity binding effectively explains the apparent discrepancy be-
tween high enzymatic activity and the great variation in reported
substrate affinities (Byeon et al., 2013; Love et al., 2012; Mitra
et al., 2014; Pham et al., 2013). As we show, affinity drops by
an order of magnitude and the Hill coefficient drops dramatically
when binding to product is compared with substrate binding.
Since most binding experiments to determine affinity are con-
ducted at equilibrium and A3A has very fast deamination rates,
experiments done with active enzyme will observe binding to
the reaction product instead of the substrate.Weaker andmono-
meric binding to product corroborates our results (Shlyakhtenko
et al., 2014); after incubation with substrate, active A3A was
observed in a predominantly monomeric form, whereas inactive
A3Awould form a dimer on substrate. A recent study in which the
catalytically deficient E72A mutant was used was also able to
measure a similarly high affinity to the ssDNA substrate (Logue
et al., 2014). In the presence of active A3A, substrate would
quickly have been turned over to product and therefore appear
to bind with low affinity. Taken together, the differences in bind-
ing product and substrate explain why binding with high affinity
and in a dimeric state could only be observed for catalytically
inactive enzyme.
A cooperative model of APOBEC3 activity also explains the
ability to achieve the required fidelity of substrate recognition
despite high deamination activity. Being the most active deami-
nase of the APOBEC3 family, A3A also serves as the most effec-
tive restrictor of foreign DNA (Stenglein et al., 2010). Less
discriminatory than other APOBEC3 enzymes and the only
known family member reported to deaminate modified cytidine
residues (Carpenter et al., 2012; Suspe`ne et al., 2013; Wije-
singhe and Bhagwat, 2012), A3A can also be implied as an agent
in demethylation pathways (Franchini et al., 2012; Guo et al.,
2011). At the same time, the random nature of mutations intro-908 Structure 23, 903–911, May 5, 2015 ª2015 Elsevier Ltd All rightsduced by A3A can be very detrimental to cell viability (Burns
et al., 2013a; Stenglein et al., 2010) or can be the source for mu-
tations in cancer, as has been shown for the close relative A3B,
the catalytic domain of which shares 97% similarity with A3A.
The cooperative model of substrate interaction for A3A can
have implications on how the mutation load inflicted by A3A is
regulated in vivo. At low concentrations and in the dense milieu
of the cell, the enzyme would encounter a short, exposed ssDNA
substratemostly asmonomer with only modest affinity. At higher
concentrations and in the presence of longer stretches of foreign
ssDNA, A3A can act with very high specificity and affinity on a
target sequence, leading to the observed high rates of deamina-
tion. Also, the change in binding affinity toward a stretch of
thymidine bases (KD = 502 ± 27 nM) upon introduction of a single
cytidine (KD = 56 ± 2) could suggest a possible mechanism of
substrate bindingwherein A3A initially binds the thymidine bases
with low affinity, followed by identifying the target cytidine and
binding more tightly.
The cooperative binding model may also provide insights into
the evolution of the APOBEC3 domain structure. Four of the
seven members of the human APOBEC3 protein family (A3B,
A3D, A3F, and A3G) comprise two cytidine deaminase domains
connected via a short linker. This repertoire of double-domain
APOBEC3 proteins likely evolved during a series of gene dupli-
cation events from single-domain precursors (Jarmuz et al.,
2002; Wedekind et al., 2003). The evolutionary linkage between
the members of the modern primate APOBEC3 locus can be un-
derstood from a prototypical set of single-domain APOBEC3
proteins, one for each Z domain subtype (LaRue et al., 2008).
In primates, A3A is the sole member comprising a single Z1
domain, sharing phylogenetic origin with the catalytic domains
of A3B and A3G. Both of these enzymes possess a pseudocata-
lytic N-terminal Z2 domain, which is required for efficient sub-
strate binding but does not catalyze a deamination reaction
(Chelico et al., 2010; Hache et al., 2005). The functional A3A
dimer identified here might provide a reason why APOBEC3reserved
Figure 4. Residues Implicated in Deamination Activity
Shown are independently determined substrate binding surfaces by enzy-
matic activity (red) (Bulliard et al., 2011) or chemical shift perturbation
accompanied by enzymatic activity (green) (Mitra et al., 2014). Residues
identified in both studies are colored yellow. See also Figure S4.might form two-domain fusions. With a single target site, one of
the A3A monomers does not act on the target cytidine but is
involved in substrate binding. The evolution of double-domain
enzymes appears to have allowed for a separation of function
between binding and catalysis leading to less active proteins
that became more specific to their target. The interdomain linker
region has recently been shown to have the determinants for
processivity in A3G and A3F and alterations in the linker can
impair enzyme function (Ara et al., 2014).
Damage in ssDNA was shown to be a major source for muta-
tion clusters in cancer (Roberts et al., 2012; Sakofsky et al., 2014)
and can also contribute to the diversity of viral genomes (Kim
et al., 2010; Sadler et al., 2010). Targeting the activity of deami-
nasesmay have implications for novel strategies in the treatment
of infectious diseases and cancer therapies and the insights into
the structural mechanism of substrate binding described in this
study could help guide efforts to alleviate the detrimental muta-
genic activity of cellular deaminases.
EXPERIMENTAL PROCEDURES
Expression and Purification of APOBEC3A- E72A-C171A
Escherichia coli BL21 DE3 Star (Stratagene) cells were transformed with a
pColdIII vector (Takara Biosciences) encoding a glutathione S-transferase
(GST)-based construct. The E72A mutation was chosen to render the protein
inactive and C171A to increase solubility. Expression occurred at 16C for
22 hr in lysogeny broth medium containing 1 mM isopropyl b-D-1-thiogalacto-
pyranoside and 100 mg/ml ampicillin. Cells were pelleted, resuspended in pu-
rification buffer (50 mM Tris-HCl [pH 8.0], 300 mM NaCl, 1 mM DTT) and dis-
rupted through sonication. Cellular debris was separated by centrifugation
(45,0003 g, 30 min, 4C). The fusion protein was separated using glutathione
Sepharose (GE Healthcare). The GST tag was removed by means of a PreSci-
ssion protease digest overnight at 4C. Size-exclusion chromatography using
a HiLoad 16/60 Superdex 75 column (GE Healthcare) was used as a final pu-
rification step.
Crystallization and Structural Data Analysis of APOBEC3A-E72A-
C171A
The protein solution was concentrated to 19.5 mg/ml in crystallization buffer
(50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM DTT, 50 mM ZnCl) and crystals
were grown at 4C in crystallization solution (100 mM sodium cacodylate
[pH 6.0], 40% 2-methyl-2,4-pentanediol, 8% PEG8000) by sitting-drop vapor
diffusion over 3 years.Structure 23Diffraction experiments were conducted using a rotating anode X-ray
source (Rigaku Micromax-007 HF) and charge-coupled device detector
(Rigaku Saturn 944) at 100 K.
Data were indexed and scaled using the software HKL2000 (Otwinowski and
Minor, 1997). CC1/2 and CC* were used to determine the data cutoff. The mo-
lecular replacement solutionwas calculated by Phaser (McCoy, 2007) using the
ProteinDataBank IDPDB:3V4Kasasearchmodel (Li et al., 2012). Thestructure
was rebuilt using phenix.autobuild (Zwart et al., 2008). An automated pipeline
(REdiii) was used for processing data from subsequent diffraction experiments
(Bohn and Schiffer, 2015). Multiple crystals were diffractedwith exposure times
between 2 and 4 min per oscillation image; only one led to diffraction spots
beyond 3 A˚. Refinement was carried out using Coot (Emsley and Cowtan,
2004) and phenix.refine (Zwart et al., 2008). Molecular graphics images were
generated using PyMOL (Schro¨dinger LLC) (DeLano, 2002). SiteMap (Halgren,
2009) was used to identify and evaluate volumes of binding sites, using a fine
grid to search around the Zn2+ atoms in the dimerization interface.
High-Throughput DNA Binding Assay
Carboxytetramethylrhodamine (50-TAMRA)-labeled ssDNA (IDT) served as
substrate (sequences are listed in Table S1). 10 nM of substrate was added
to A3A-E72A-C171A in concentrations varying between 10 nM and 20 mM,
and to a control without protein. The A3A protein concentrations were 0, 10,
25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, and
750 nM; 1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, and 20 mM. The mixtures
were incubated for 1 hr at room temperature in nonbinding 96-well
plates (Greiner) in 50 mM MES buffer (pH 6.0), 100 mM NaCl, 2 mM
tris(2-carboxyethyl)phosphine in a total reaction volume of 150 ml per well.
Fluorescence anisotropy was measured for triplicate experiments using an
EnVision plate reader (PerkinElmer) equipped with the Optimized Tamra
Acyclo Prime SNP Label detection kit, allowing excitation at 531 nm and
detection of polarized emission at 579 nm wavelength. Data analysis was per-
formed using Prism (GraphPad) performing least-square fitting of the
measured fluorescence anisotropy values (Y) at different protein concentra-
tions (X) with a single-site binding curve with Hill slope, a nonspecific linear
term, and a constant background using the equation Y=(Bmax 3 X^h)/
(Kd^h + X^h) + NS3 X + Background, where Kd is the equilibrium dissociation
constant, h is the Hill coefficient, and Bmax is the extrapolated maximum
anisotropy at complete binding. SD was calculated for each measurement
point from the three independent repeats and is shown as error bars in the
corresponding data figures.
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